AbbVie, Inc. (ABBV)

93.27
1.00 1.10
NYSE
Prev Close 94.29
Open 94.47
Day Low/High 93.19 / 94.80
52 Wk Low/High 62.55 / 101.28
Volume 5.02M
Exchange NYSE
Shares Outstanding 1762.34B
Market Cap 169.08B
P/E Ratio 16.92
Div & Yield N.A. (N.A)
Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

Jim Cramer: No Place to Go and Fewer Places to Hide

Jim Cramer: No Place to Go and Fewer Places to Hide

Just not a great day.

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Traders should still be long and looking for higher highs. Let's check the charts and indicators again.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.

Activating My Dip-Buying Shopping List

Activating My Dip-Buying Shopping List

I added to two positions Tuesday, as growth catalysts are in play this earnings season.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

AbbVie Could Climb Even Higher

AbbVie Could Climb Even Higher

AbbVie prices are way above the rising 50-day moving average line.

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Currency traders see the Trump administration boosting manufacturing via a weak dollar.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.

AbbVie Is Likely to Correct: Book Some Profits

AbbVie Is Likely to Correct: Book Some Profits

ABBV has gone 'vertical' on the daily chart.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

AbbVie Is Flexing Its Abs

AbbVie Is Flexing Its Abs

ABBV is now set up well for more upside.

A Trio of Stocks Up on Nice Results

The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily ...

Early-Morning Earnings Extravaganza

It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.